Plas-Free and the EIC Accelerator: A Filter for Plasma
Patients with massive bleeding receive plasma transfusions to help their blood clot. Plas-Free, a company founded in 2017 in Nazareth, Israel, developed ClearPlasma, a single-use filter that the EU project report says "significantly reduces the concentration of the target protein by >90%, without altering other coagulation parameters", to make transfused plasma more effective.
The European Innovation Council granted €1,279,184 towards a €1.83 million project that enrolled 56 patients in four European hospitals and built an industrial mould able to make more than 100,000 kits. According to its news page, ClearPlasma received a CE mark under the EU Medical Device Regulation in October 2025. The company has not reported sales.
Company file
- Legal entity
- Plas-Free Ltd., Nazareth, Israel
- Founded
- 2017
- Products
- ClearPlasma; AAPC-300 in pipeline
- Regulatory
- CE mark (MDR), October 2025; ISO 13485
- Clinical sites
- Including Gemelli, Rome; hospitals in Israel
- Earlier EU support
- Seal of Excellence (2019); SME Instrument Phase 1 (2020)
- EIC project
- ClearPlasma, 1 Feb 2022 to 31 Jul 2023, closed
- EIC funding
- Blended finance
Where Plas-Free Stands Today
Plas-Free's news page lists the CE mark in October 2025, renewed ISO 13485 certification in April 2025 and an award at the Health Tech Challengers competition in December 2025. Its overview describes a "clinical stage HealthTech company" developing "vital fluid absorbent devices for blood purification", with ClearPlasma and a second product, AAPC-300. It names no distributor or hospital customer and no funding since 2021.
The Technology: A Filter for Donated Plasma
ClearPlasma treats plasma units before transfusion. According to the CORDIS report, it removes more than 90% of a target protein without changing other clotting factors, and "no adverse events occurred using Clear Plasma compared to regular plasma transfusion". Earlier, the company completed an open-label phase in five patients with upper gastrointestinal bleeding in Israel and at Gemelli hospital in Rome.
"No adverse events occurred using Clear Plasma compared to regular plasma transfusion."
ClearPlasma results, CORDISWhat the EIC Project Promised, and What CORDIS Shows
The EIC project
The EU paid 70% of a €1.83M project
ClearPlasma ran from February 2022 to July 2023. The award was blended finance.
CORDIS project 190181669. Values in € millions.
The project promised "an innovative filtration system to improve the coagulation properties of plasma units to treat patients with massive bleeding". CORDIS reports 56 patients enrolled in four European hospitals, 600 units manufactured for trials, an industrial mould for more than 100,000 kits and the clinical file submitted for CE marking, which the company says was granted two years after the project ended. It does not publish efficacy results beyond the protein reduction and safety.
The manufacturing
Units made for trials, and what the mould can make
ClearPlasma units produced for clinical trials during the project, and the number of kits the industrial mould built in the project is designed to produce.
CORDIS project 190181669 results.
- A clinical studyDelivered56 patients, 4 hospitals.
- Industrial productionDeliveredMould for 100,000+ kits.
- CE markDeliveredOctober 2025.
- Sales to hospitalsNot shownNone reported.
What Has Happened Since the Award
The record
From pig model to a CE mark
Plas-Free finished its clinical study and manufacturing scale-up under the EIC project; the CE mark followed in October 2025.
- 2017FoundedPlas-Free, Nazareth
- Apr 2018PreclinicalPig liver laceration model
- Dec 2020First clinical studyClearPlasma in upper gastrointestinal bleeding
- Dec 2021EIC awardAbout €1.8M grant plus €2.1M investment, per the company
- Feb 2022EIC project startsClinical study, industrial mould, CE submission€1.28M grant
- Jul 2023EIC project ends56 patients in 4 European hospitals; 600 units made
- Oct 2025CE markClearPlasma certified under the EU MDR
Plas-Free and CORDIS.
The Money
Plas-Free's news page says the EIC jury recommended it for "approximately €1.8M grant plus €2.1M investment" in December 2021; CORDIS records the grant at €1.28 million. Plas-Free appears among the EIC Fund's invested companies, which confirms the equity part was invested; the amount is not given. We found no other funding round. Israeli company records were not accessible for this article.
What cannot be checked
How much the EIC Fund invested, whether any hospitals buy ClearPlasma, the clinical efficacy data and Plas-Free's finances are not public.
Why Europe Should Care
The project targeted patients with massive bleeding, for whom plasma transfusion is part of treatment. The EIC funded the clinical and manufacturing steps, and the company says the device is now approved for the EU market. Whether it is used is the next question.
What the project promised
A filtration system to improve plasma units for patients with massive bleeding.
What the record shows
A 56-patient study, industrial tooling and a CE mark; no reported sales or new funding.
The Verdict
Approved, not yet visible in hospitals
By the company's account, ClearPlasma is one of the EIC projects that reached regulatory approval, if two years after the project ended. What the public record lacks is any sign of use or sales, and the amount of equity Plas-Free received is not given.
Plas-Free has not been asked for comment for this article. It is based entirely on company statements and EU project data, linked throughout.
Industry
HealthMedical devices
- Focus
- Haematology devices
- Technologies
- Filtration
- Keywords
- Plasma transfusion
- Bleeding
- Blood products
- Blood purification